Tag: cells

KUALA LUMPUR, Malaysia, June 17, 2025 (GLOBE NEWSWIRE) -- Founder Group Limited (NASDAQ: FGL) (“Founder Group” or the “Company”), a leading engineering, procurement, construction, and commissioning (EPCC) solutions provider for solar photovoltaic systems in Malaysia, is pleased to announce the signing of a memorandum of understanding (MOU) with GCL Systems Integration Technology Co. Ltd. (GCL). The companies have agreed to cooperate and work together to explore, identify, assess and undertake projects focused on the Renewable Energy industry across Malaysia and other ASEAN countries with an estimated value of up to USD $220 million.

SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of  engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo’s Orphan Drug Designation (ODD) for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 is an innovative therapy that engineers a cancer patient's own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells.

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications -

Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include recent corporate milestones and research advances using fibroblast-based technology for indications such as wound healing, multiple sclerosis, and psoriasis.

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

Garching / Munich, Germany, and Grenoble, France, June 16, 2025 – ITM Isotope Technologies Munich SE (ITM) and the Institut Laue-Langevin (ILL), today announced an extension of their collaboration for medical radioisotope production, originally established in 2009. Under the terms of the renewed agreement, ITM will receive priority access to half of the available neutron irradiation capacity at ILL’s High-Flux Reactor, its neutron irradiation facility, for the production of non-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used for radiopharmaceutical therapies for cancer treatment and diagnosis. As the globally leading manufacturer of n.c.a. Lu-177, ITM is committed to maintaining and expanding its robust manufacturing and production capabilities to meet the growing demand for this vital medical radioisotope.

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.